A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol

被引：0
|
作者：
Anjali K. Bhardwaj
Llew Mills
Michael Doyle
Arshman Sahid
Mark Montebello
Lauren Monds
Shalini Arunogiri
Paul Haber
Valentina Lorenzetti
Dan I. Lubman
Peter Malouf
Mary E. Harrod
Adrian Dunlop
Tom Freeman
Nicholas Lintzeris
机构：
[1] University of Sydney,Faculty of Medicine
[2] South East Sydney Local Health District,Drug and Alcohol Services
[3] North Sydney Local Health District,Drug and Alcohol Services
[4] Centre for Addiction and Mental Health,Drug Health Services
[5] Turning Point,Faculty of Health Science
[6] Sydney Local Health District,Medicine and Health
[7] Australian Catholic University,Drug and Alcohol Clinical Services
[8] University of New South Wales,Addiction and Mental Health Group
[9] NSW Users and AIDS Association,undefined
[10] Hunter New England Local Health District,undefined
[11] University of Bath,undefined
来源：
BMC Psychiatry | / 24卷
关键词：
Cannabis; Cannabis withdrawal; Cannabis use disorder; Cannabidiol; Marijuana; Study protocol;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol
    Bhardwaj, Anjali K.
    Mills, Llew
    Doyle, Michael
    Sahid, Arshman
    Montebello, Mark
    Monds, Lauren
    Arunogiri, Shalini
    Haber, Paul
    Lorenzetti, Valentina
    Lubman, Dan I.
    Malouf, Peter
    Harrod, Mary E.
    Dunlop, Adrian
    Freeman, Tom
    Lintzeris, Nicholas
    [J]. BMC PSYCHIATRY, 2024, 24 (01)
  • [2] A randomised controlled trial of cannabidiol for the treatment of cannabis use disorder: A study protocol
    Lintzeris, Nicholas
    Bhardwaj, Anjali
    Lubman, Dan I.
    Doyle, Michael
    Dunlop, Adrian J.
    Mills, Llewellyn
    Harrod, Mary E.
    Arunogiri, Shalini
    Malouf, Peter
    Haber, Paul S.
    Freeman, Tomp.
    Montebello, Mark E.
    Graham, Robert
    Childs, Steven
    Monds, Lauren A.
    Jeffries, Meryem
    Nean, Martin
    Ella, Stephen
    [J]. DRUG AND ALCOHOL REVIEW, 2023, 42 : S109 - S109
  • [3] Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial
    Freeman, Tom P.
    Hindocha, Chandni
    Baio, Gianluca
    Shaban, Natacha D. C.
    Thomas, Emily M.
    Astbury, Danica
    Freeman, Abigail M.
    Lees, Rachel
    Craft, Sam
    Morrison, Paul D.
    Bloomfield, Michael A. P.
    O'Ryan, Dominic
    Kinghorn, Jane
    Morgan, Celia J. A.
    Mofeez, Ali
    Curran, H. Valerie
    [J]. LANCET PSYCHIATRY, 2020, 7 (10): : 865 - 874
  • [4] Cannabidiol for the treatment of cannabis use disorder: Phase IIa double-blind placebo-controlled randomised adaptive Bayesian dose-finding trial
    Freeman, Tom
    [J]. INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2021, 28 (SUPPL 1) : S39 - S39
  • [5] Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder
    Daniel Ying-Heng Hua
    Chandni Hindocha
    Gianluca Baio
    Rachel Lees
    Natacha Shaban
    Celia J. Morgan
    Ali Mofeez
    H. Valerie Curran
    Tom P. Freeman
    [J]. Translational Psychiatry, 13
  • [6] Effects of cannabidiol on anandamide levels in individuals with cannabis use disorder: findings from a randomised clinical trial for the treatment of cannabis use disorder
    Hua, Daniel Ying-Heng
    Hindocha, Chandni
    Baio, Gianluca
    Lees, Rachel
    Shaban, Natacha
    Morgan, Celia J. J.
    Mofeez, Ali
    Curran, H. Valerie
    Freeman, Tom P. P.
    [J]. TRANSLATIONAL PSYCHIATRY, 2023, 13 (01)
  • [7] The neurobehavioural effects of cannabidiol in alcohol use disorder: Study protocol for a double-blind, randomised, cross over, placebo-controlled trial
    Hurzeler, Tristan P.
    Logge, Warren
    Watt, Joshua
    DeMayo, Marilena M.
    Suraev, Anastasia
    McGregor, Iain S.
    Haber, Paul S.
    Morley, Kirsten C.
    [J]. CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS, 2024, 41
  • [8] Use of Cannabidiol (CBD) oil in the treatment of PTSD: Study design and rationale for a placebo-controlled randomized clinical trial
    Telch, Michael J.
    Fischer, Caitlin M.
    Zaizar, Eric D.
    Rubin, Mikael
    Papini, Santiago
    [J]. CONTEMPORARY CLINICAL TRIALS, 2022, 122
  • [9] Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial
    McRae-Clark, Aimee L.
    Gray, Kevin M.
    Baker, Nathaniel L.
    Sherman, Brian J.
    Squeglia, Lindsay
    Sahlem, Gregory L.
    Wagner, Amanda
    Tomko, Rachel
    [J]. DRUG AND ALCOHOL DEPENDENCE, 2021, 229
  • [10] Study protocol for a phase II, double-blind, randomised controlled trial of cannabidiol (CBD) compared with placebo for reduction of brain neuroinflammation in adults with chronic low back pain
    Pike, Chelsea K.
    Kim, Minhae
    Schnitzer, Kristina
    Mercaldo, Nathaniel
    Edwards, Robert
    Napadow, Vitaly
    Zhang, Yi
    Morrissey, Erin Janas
    Alshelh, Zeynab
    Evins, A. Eden
    Loggia, Marco L.
    Gilman, Jodi M.
    [J]. BMJ OPEN, 2022, 12 (09):
12345